Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27632662 | 0.89 | SLC7A5 (0.39) | TMEM97ROCK2ROCK1LOXL2RAB9A | |
| SCHEMBL27613531 | 0.83 | PTGS2 (0.33) | KMT2APTGS2ALDH1A1 | |
| SCHEMBL3264797 | 0.73 | CA12 (0.40) | CA1CA2CA4CA12CA9 | |
| SCHEMBL13525150 | 0.71 | CA12 (0.56) | CA1CA2CA4CA12CA9 | |
| SCHEMBL3264798 | 0.69 | CA12 (0.45) | CA1CA2CA4CA12CA9 | |
| SCHEMBL3108498 | 0.69 | CA1 (0.41) | CA1CA2CA4CA12CA9 | |
| SCHEMBL13546028 | 0.68 | CYP4F2 (0.56) | CA1CA2CA4CA12CA9 | |
| SCHEMBL3780102 | 0.66 | CA12 (0.39) | CA1CA2CA4CA12CA9 | |
| SCHEMBL186313 | 0.65 | CA12 (0.56) | CA1CA2CA4CA12CA9 | |
| SCHEMBL2958012 | 0.64 | CA12 (0.64) | CA1CA2CA4CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858665-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-12-28 | — | — | US | claimed |
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | NICOX SA (FR) | 2009-09-24 | — | — | US | claimed |
| US-20060270608-A1 | Drugs for chronic pain | NICOX S.A. (FR) | 2006-11-30 | — | — | US | claimed |
| US-7642289-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-01-05 | — | — | US | disclosed |
| US-20060270608-A1 | Drugs for chronic pain | NICOX S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | OPRK1, OPRL1, OPRD1 | CA1 1813/4885CA2 860/4885CA4 2655/4885 |
| US-20060270608-A1 | Drugs for chronic pain | OPRK1, OPRL1, OPRD1 | CA1 1813/4885CA2 860/4885CA4 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.